Back to School: How biopharma can reboot drug development. Access exclusive analysis here
An open-label, dose-escalation, U.S. Phase I trial in 28 patients with CRPC showed that the recommended Phase II dose of IV DSTP3086S was 2.8
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury